Children's Oncology Group's 2013 blueprint for research: Renal tumors

Jeffrey S. Dome*, Conrad V. Fernandez, Elizabeth A. Mullen, John A. Kalapurakal, James I. Geller, Vicki Huff, Eric J. Gratias, David B. Dix, Peter F. Ehrlich, Geetika Khanna, Marcio H. Malogolowkin, James R. Anderson, Arlene Naranjo, Elizabeth J. Perlman

*Corresponding author for this work

Research output: Contribution to journalReview article

76 Scopus citations


Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.

Original languageEnglish (US)
Pages (from-to)994-1000
Number of pages7
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 1 2013



  • Clear cell sarcoma
  • Malignant rhabdoid tumor
  • Renal cell carcinoma
  • Wilms tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Dome, J. S., Fernandez, C. V., Mullen, E. A., Kalapurakal, J. A., Geller, J. I., Huff, V., Gratias, E. J., Dix, D. B., Ehrlich, P. F., Khanna, G., Malogolowkin, M. H., Anderson, J. R., Naranjo, A., & Perlman, E. J. (2013). Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatric Blood and Cancer, 60(6), 994-1000.